多参数磁共振成像评估非酒精性脂肪性肝病的效用与成本评价
研究前瞻性纳入英国两个肝病中心接受标准肝活检的成人NAFLD患者,比较多参数MRI与现有无创标志物的诊断性能及成本。结果显示cT1与NAFLD活动评分相关,多参数MRI可区分单纯性脂肪变与NASH并可靠排除临床显著肝病,阴性预测值优于肝硬度及ELF,风险分层中较活检节省费用。
要点
- cT1与NAFLD活动评分相关(ρ=0.514,P<.001)。
- 多参数MRI排除临床显著肝病的阴性预测值为83.3%,高于肝硬度42.9%和ELF 57.1%。
- 风险分层中多参数MRI每1000例患者较活检节省£150,218。
核心结论
- 多参数MRI能准确识别脂肪变患者,区分NASH与单纯性脂肪变,并可靠排除临床显著肝病,阴性预测值优于肝硬度和ELF。
- 在NAFLD风险分层中,多参数MRI具有成本效益,与瞬时弹性成像联合时每正确诊断成本最低。
研究设计与样本
- 前瞻性研究,在英国两个肝病中心招募接受标准肝活检的成人NAFLD患者,肝活检后2周内完成多参数MRI、采血和瞬时弹性成像。
- 共获得50例患者和6名健康志愿者的数据,以组织学为金标准比较无创标志物。
主要发现
- 校正T1(cT1)与NAFLD活动评分相关(ρ=0.514,P<.001)。
- cT1、增强肝纤维化(ELF)检测和肝硬度区分单纯性脂肪变与NASH的AUROC(95%CI)分别为0.69(0.50-0.88)、0.87(0.77-0.79)和0.82(0.70-0.94)。
- cT1、ELF和肝硬度区分健康志愿者与患者的AUROC(95%CI)分别为0.93(0.86-1.00)、0.81(0.69-0.92)和0.89(0.77-1.00)。
- 多参数MRI在该人群中未能区分单个组织学纤维化分期(P=.068)。
- 多参数MRI排除临床显著肝病的阴性预测值为83.3%,肝硬度为42.9%,ELF为57.1%。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 多参数MRI在该人群中未能区分单个组织学纤维化分期(P=.068)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Validated diagnostic tools that are accurate, cost effective and acceptable to patients are required for disease stratification and monitoring in NAFLD. AIMS: To investigate the performance and cost of multiparametric MRI alongside existing biomarkers in the assessment of NAFLD. METHODS: Adult patients undergoing standard of care liver biopsy for NAFLD were prospectively recruited at two UK liver centres and underwent multiparametric MRI, blood sampling and transient elastography withing 2 weeks of liver biopsy. Non-invasive markers were compared to histology as the gold standard. RESULTS: Data were obtained in 50 patients and 6 healthy volunteers. Corrected T1 (cT1) correlated with NAFLD activity score (ρ = 0.514, P < .001). cT1, enhanced liver fibrosis (ELF) test and liver stiffness differentiated patients with simple steatosis and NASH with AUROC (95% CI) of 0.69 (0.50-0.88), 0.87 (0.77-0.79) and 0.82 (0.70-0.94) respectively and healthy volunteers from patients with AUROC (95% CI) of 0.93 (0.86-1.00), 0.81 (0.69-0.92) and 0.89 (0.77-1.00) respectively. For the risk stratification of NAFLD, multiparametric MRI could save £150,218 per 1000 patients compared to biopsy. Multiparametric MRI did not discriminate between individual histological fibrosis stages in this population (P = .068). CONCLUSIONS: Multiparametric MRI accurately identified patients with steatosis, stratifies those with NASH or simple steatosis and reliably excludes clinically significant liver disease with superior negative predictive value (83.3%) to liver stiffness (42.9%) and ELF (57.1%). For the risk stratification of NAFLD, multiparametric MRI was cost effective and, combined with transient elastography, had the lowest cost per correct diagnosis.
引用
- Eddowes PJ, McDonald N, Davies N, et al. Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2017. PMID: 29271504. doi:10.1111/apt.14469
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。